Remodulin Treprostinil Injection

1. Indications and Usage
Pulmonary Arterial Hypertension (PAH):
Indicated for the treatment of PAH (WHO Group 1) to reduce symptoms associated with exercise.
Approved for use in patients with PAH associated with congenital heart disease.
Route of Administration:
Administered via continuous subcutaneous (SC) or intravenous (IV) infusion.
2. Dosage and Administration
Initial Dosage:
The recommended starting dose is 1.25 ng/kg/min (either SC or IV).
For patients who cannot tolerate this initial dose due to systemic effects (e.g., headache, nausea), the rate may be reduced to 0.625 ng/kg/min.
Titration:
Increase the infusion rate in small increments (e.g., 1.25 ng/kg/min for the first 4 weeks, then 2.5 ng/kg/min thereafter) based on clinical response and tolerability.
Administration Instructions:
Subcutaneous: Preferred route. Administered via a dedicated pump using a catheter inserted subcutaneously (usually the abdominal wall).
Intravenous: Administered via a central venous catheter. Peripheral IV use is limited to short-term due to the risk of thrombophlebitis.
Dilution: If dilution is required, use Sterile Water for Injection or 0.9% Sodium Chloride Injection.
Missed Dose/Interruption:
Do not abruptly stop the infusion.
If the infusion is interrupted for a short period (hours), resume at the same rate.
If interruption is prolonged, re-titration of the dose is required.
3. Mechanism of Action
Prostacyclin Analogue:
Treprostinil is a potent, long-acting, stable analogue of endogenous prostacyclin (PGI2).
Vasodilation:
It directly dilates pulmonary and systemic arterial vascular beds.
Antiplatelet Effects:
It inhibits platelet aggregation.
Pathophysiology:
In PAH, there is a deficiency of endogenous prostacyclin. Treprostinil replaces this deficiency, reducing pulmonary vascular resistance and right ventricular afterload.
4. Safety and Warnings
Systemic Hypotension:
Due to its vasodilatory properties, sudden withdrawal or rapid dose reduction may lead to rebound pulmonary hypertension or hypotension.
Infusion Site Complications:
SC: Pain and site reactions (rash, erythema, induration) are very common and may limit dose escalation.
IV: Risk of bloodstream infections and sepsis. Strict aseptic technique is mandatory.
Bleeding Risk:
Treprostinil inhibits platelet aggregation, which may increase the risk of bleeding, especially in patients on anticoagulation therapy.
Fluid Retention:
May cause fluid retention, which can be problematic in patients with right ventricular failure.
5. Adverse Reactions
Most Common (SC):
Injection site pain (very common), injection site reaction, headache, diarrhea, nausea, jaw pain, and flushing.
Most Common (IV):
Headache, diarrhea, nausea, vomiting, and infection at the catheter site.
6. Drug Interactions
Antihypertensives/Other Vasodilators:
Concomitant use with diuretics, antihypertensive drugs, or other vasodilators may increase the risk of symptomatic hypotension.
Anticoagulants/Antiplatelets:
Concomitant use may increase the risk of bleeding.
CYP Enzymes:
Treprostinil is metabolized primarily by CYP2C8. Co-administration with CYP2C8 inhibitors (e.g., gemfibrozil) may increase exposure, while inducers (e.g., rifampin) may decrease it.
7. Pharmaceutical Information
Chemical Composition:
Active Ingredient: Treprostinil (as the sodium salt).
Excipients: Sodium Citrate Dihydrate, Hydrochloric Acid, Metacresol, Sodium Hydroxide, Sodium Chloride, and Water for Injection.
Appearance:
Clear, colorless to slightly yellow solution.
Storage:
Store at 20°C to 25°C (68°F to 77°F). Protect from light.